Better medicines for children: challenges and unmet needs

J. Slažneva 1 , V. Kákošová 2 , and M. Kuželová 1
  • 1 Faculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius University in Bratislava
  • 2 Hospital pharmacy, University Children's hospital, Bratislava

Better medicines for children: challenges and unmet needs

This review deals with the use of medicinal products in children. Many medicinal products administered routinely to paediatric patients have been either not licensed for use in children (unlicensed use) or have been prescribed outside the terms of their product license (off-label prescribing). A lot of surveys have been conducted in the context of identifying the extent of off-label used drugs in children documenting high rates (45-60 %) of such use. Recognising and meeting challenges as development of suitable formulations for very young children and realization of clinical trials involving children present important steps in the enhancement of the present situation. To improve the health of children in Europe, the Regulation (EC) No 1901/2006 addressing the pharmaceutical industry, research teams and member states proposing important incentives and obligations was assigned. Paediatric Investigation Plan and Paediatric Use Marketing Authorisation present the key measures of the EU regulation on medicinal products for paediatric patients.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council; on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004- of 12 December 2006. Available at:

  • BUSH, A.: Evidence-based medicines for children: important implications for new therapies at all ages. EurRespir J 28, 2006, p. 1069-1072.

  • PERMANAND, G. - MOSSIALOS, E. - MCKEE, M.: The EU's new paediatric medicines legislation: serving children's needs? Arch Dis Child 92, 2007, p. 808-811.

  • HOPPU, K.: Paediatric clinical pharmacology - at the beginning of a new era. Eur J ClinPharmacol64, 2008, p. 201-205.

  • LINDELL-OSUAGWU, L. - KORHONEN, M.J. - SAANO, S. - HELIN-TANNINEN, M. - NAARANLAHTI, T. - KOKKI, H.: Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34, 2009, p. 277-287.

  • A guideline on summary of product characteristics. Available at:

  • ERNEST, T. B. - ELDER, D. P. - MARTINI, L. G. - ROBERTS, M. - FORD, J. L.: Developing paediatric medicines: identifying the needs and recognizing the challenges. J Clin Pharm Ther 59, 2007, p. 1043-1055.

  • CONSTABLE, S. - WINSTANLEY, P. - WALLEY, T.: Medical Pharmacology. Third edition, Churchill Livingstone Elsevier 2007, p. 278-279.

  • EMA. Reflection paper: formulation of choice for the paediatric population. 2006. EMEA/CHMP/PEG/194810/2005.

  • FORTWENGEL, G. - OSTERMANN, H. - STAUDINGER, R.: Better medicines for children: Clinical Investigation of Medicinal Products in the Paediatric Population - A QA Perspective. Published online in Wiley InterScience. DOI: 10.1002/qaj.422.

  • BREITKREUTZ, J.: European Perspectives on Paediatric Formulations. ClinTher 30, 2008, p. 2146-2154.

  • DELL'AERA, M. - GASBARRO, A. R. - PADOVANO, M. - LAFORGIA, N. - CAPODIFERRO, D. - SOLARINO, B. - QUARANTA, R. - DELL'ERBA, S. A.: Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci 29, 2007, p. 361-367.

  • DICK, A. - KEADY, S. - MOHAMED, F. - BRAYLEY, S. - THOMSON, M. - LLOYD, B.W. - HEUSCHKEL, R. - AFZAL, N. A.: Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Aliment PharmacolTher 17, 2003, p. 571-575.

  • Report on the survey of all paediatric uses of medicinal products in Europe. Available at:


Journal + Issues